靶点- |
|
|
|
|
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期- |
Phase 1/2a Study for Treatment of Chronic Diabetic Foot Ulcers (DFU) With the Investigational Allogeneic Cell Therapy Product, hOMSC200
Purpose of this phase 1/2a study is to assess the safety and efficacy of administration of allogeneic human oral mucosal stem cells (hOMSCs) in patients suffering from chronic diabetic foot ulcers (DFU).
100 项与 Cytora Ltd. 相关的临床结果
0 项与 Cytora Ltd. 相关的专利(医药)
100 项与 Cytora Ltd. 相关的药物交易
100 项与 Cytora Ltd. 相关的转化医学